Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML

Toshiki Terao; Ken Ichi Matsuoka; Hiroko Ueda; Akifumi Matsumura; Chisato Matsubara; Kaho Kondo; Takumi Kondo; Hideaki Fujiwara; Noboru Asada; Daisuke Ennishi; Hisakazu Nishimori; Keiko Fujii; Nobuharu Fujii; Yoshinobu Maeda

doi:10.1182/bloodadvances.2022008991

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3^mut AML

Toshiki Terao, Ken Ichi Matsuoka, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	681-686
Number of pages	6
Journal	Blood Advances
Volume	7
Issue number	5
DOIs	https://doi.org/10.1182/bloodadvances.2022008991
Publication status	Published - Mar 14 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2022008991

Cite this

Terao, T., Matsuoka, K. I., Ueda, H., Matsumura, A., Matsubara, C., Kondo, K., Kondo, T., Fujiwara, H., Asada, N., Ennishi, D., Nishimori, H., Fujii, K., Fujii, N., & Maeda, Y. (2023). Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3^mut AML. Blood Advances, 7(5), 681-686. https://doi.org/10.1182/bloodadvances.2022008991

Terao, T, Matsuoka, KI, Ueda, H, Matsumura, A, Matsubara, C, Kondo, K, Kondo, T , Fujiwara, H , Asada, N , Ennishi, D, Nishimori, H, Fujii, K , Fujii, N & Maeda, Y 2023, 'Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3^mut AML', Blood Advances, vol. 7, no. 5, pp. 681-686. https://doi.org/10.1182/bloodadvances.2022008991

@article{9e080a0459af46daab69fc253a66c7bd,

title = "Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML",

author = "Toshiki Terao and Matsuoka, {Ken Ichi} and Hiroko Ueda and Akifumi Matsumura and Chisato Matsubara and Kaho Kondo and Takumi Kondo and Hideaki Fujiwara and Noboru Asada and Daisuke Ennishi and Hisakazu Nishimori and Keiko Fujii and Nobuharu Fujii and Yoshinobu Maeda",

note = "Funding Information: Acknowledgments: The authors thank the patients with hematologic malignancy, their families, and the medical staff of the Department of Hematology and Oncology of Okayama University Hospital. They also thank Hiroki Kobayashi (Department of Hematology and Oncology, Okayama University Hospital) and Kentaro Narita (Department of Hematology and Oncology, Kameda Medical Center) for their advice from a statistical perspective and Editage (https://www.editage.jp/) for English language editing. The authors did not receive financial support from any organization for the submitted work. This work was supported by a research fund from the Japan Society for the Promotion of Science KAKENHI (grant number 26461449).",

year = "2023",

month = mar,

day = "14",

doi = "10.1182/bloodadvances.2022008991",

language = "English",

volume = "7",

pages = "681--686",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML

AU - Terao, Toshiki

AU - Matsuoka, Ken Ichi

AU - Ueda, Hiroko

AU - Matsumura, Akifumi

AU - Matsubara, Chisato

AU - Kondo, Kaho

AU - Kondo, Takumi

AU - Fujiwara, Hideaki

AU - Asada, Noboru

AU - Ennishi, Daisuke

AU - Nishimori, Hisakazu

AU - Fujii, Keiko

AU - Fujii, Nobuharu

AU - Maeda, Yoshinobu

N1 - Funding Information: Acknowledgments: The authors thank the patients with hematologic malignancy, their families, and the medical staff of the Department of Hematology and Oncology of Okayama University Hospital. They also thank Hiroki Kobayashi (Department of Hematology and Oncology, Okayama University Hospital) and Kentaro Narita (Department of Hematology and Oncology, Kameda Medical Center) for their advice from a statistical perspective and Editage (https://www.editage.jp/) for English language editing. The authors did not receive financial support from any organization for the submitted work. This work was supported by a research fund from the Japan Society for the Promotion of Science KAKENHI (grant number 26461449).

PY - 2023/3/14

Y1 - 2023/3/14

UR - http://www.scopus.com/inward/record.url?scp=85150472752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150472752&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2022008991

DO - 10.1182/bloodadvances.2022008991

M3 - Article

C2 - 36583677

AN - SCOPUS:85150472752

SN - 2473-9529

VL - 7

SP - 681

EP - 686

JO - Blood Advances

JF - Blood Advances

IS - 5

ER -

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3^mut AML